Related Experiment Video

Updated: Jan 7, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K

Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients

Jordi Bruix1

  • 1BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Villarroel 170, Barcelona 08036, Spain.

Hepatic Oncology
|September 8, 2018
PubMed

Insights

Dr. Jordi Bruix pioneered advancements in liver cancer care, developing the Barcelona Clinic Liver Cancer (BCLC) staging system and diagnostic criteria for hepatocellular carcinoma (HCC). His work significantly improved treatment strategies and patient prognosis.

Area of Science:

  • Hepatology and Oncology
  • Liver Cancer Research
  • Clinical Trial Design

Background:

  • Hepatocellular carcinoma (HCC) presents complex diagnostic and treatment challenges.
  • Effective staging and treatment guidelines are crucial for improving patient outcomes.
  • Dr. Jordi Bruix's extensive research has significantly impacted the field of liver cancer.

Purpose of the Study:

  • To highlight the seminal contributions of Dr. Jordi Bruix to the diagnosis and treatment of liver cancer.
  • To underscore the development and impact of the Barcelona Clinic Liver Cancer (BCLC) staging and treatment system.
  • To emphasize the establishment of diagnostic criteria for hepatocellular carcinoma and prognostic indicators.

Main Methods:

  • Development of the BCLC staging and treatment algorithm.
  • Establishment of diagnostic criteria for hepatocellular carcinoma.
  • Investigation of portal pressure in predicting prognosis post-resection.
  • Leading Phase III clinical trials for liver cancer therapies.

Main Results:

  • The BCLC staging system has become a cornerstone in liver cancer management.
  • Validated diagnostic criteria for HCC have improved early detection and characterization.
  • Portal pressure is a validated prognostic factor for patients undergoing resection.
  • Phase III trials confirmed the efficacy of chemoembolization, sorafenib, and regorafenib for HCC treatment.

Conclusions:

  • Dr. Bruix's research has fundamentally reshaped the approach to liver cancer diagnosis and treatment.
  • His work has led to improved patient stratification, therapeutic options, and survival rates.
  • The established guidelines and criteria continue to influence clinical practice and research globally.

Keywords:
hepatocellular carcinomarandomized controlled trialregorafenibsorafenibsurvivaltreatment

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
413
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
418